Physician profile

Bennett I Machanic

Neurology (Psychiatry & Neurology) · Denver, CO

NPI 1952352593

$4,357.47

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,153.62 2019-2020
Genzyme Corporation $649.60 2019-2020
Teva Pharmaceuticals USA, INC. $470.93 2019-2020
Alexion Pharmaceuticals, INC. $381.64 2019-2021
Biogen, INC. $297.56 2019
Mallinckrodt Enterprises LLC $281.91 2019
Ucb, INC. $259.24 2019-2020
Genentech USA, INC. $228.72 2019-2020
Neurocrine Biosciences, INC. $168.79 2019
Allergan, INC. $123.54 2019-2020
Assertio Therapeutics, INC. $97.46 2019-2020
Avanir Pharmaceuticals, INC. $57.09 2019
Vertical Pharmaceuticals, LLC $40.40 2019-2020
Boston Scientific Corporation $34.85 2019
Neurelis, INC. $34.62 2020-2021
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Emd Serono, INC. $26.64 2019
Mallinckrodt Hospital Products INC. $20.98 2020
Grifols USA, LLC $18.78 2019
Csl Behring $11.10 2019

6 companies reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bennett I Machanic

$4,357.47

in general payments reported 2019-2025

Years
2019-2021
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/134340/bennett-i-machanic

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.